Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
Study Purpose
A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes
Recruitment Criteria
|
Accepts Healthy Volunteers
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms |
No |
|
Study Type
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies. |
Interventional |
| Eligible Ages | 12 Years and Over |
| Gender | All |
Inclusion Criteria:
1. Patients must have a malignant solid tumor with a pathogenic inactivating TSC1 or TSC2 alteration. Genetic alterations should be identified using NGS in tumor tissue or liquid biopsy). • Patients will be enrolled after the central evaluation of NGS report confirms eligibility. 2. Patients must have solid tumors that are metastatic or locally advanced where surgical resection is not an option or likely to result in severe morbidity. 3. Patients must have received all standard therapies appropriate for their tumor type and stage of disease or, in the opinion of the Investigator, the patient would be unlikely to tolerate or derive clinically meaningful benefit from appropriate standard of care therapy, or the patient has no satisfactory alternative treatments. 4. Patients must have 1 or more measurable target lesions by computed tomography (CT) scan or magnetic resonance imaging (MRI) (RECIST v1.1). 5. Age: 12 years or older. 6. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 or Karnofsky Performance Status (KPS) ≥80 or Lansky play-performance scale for pediatric patients ≥80. 7. Adequate liver function: 1. Total bilirubin ≤1.5 × upper limit of normal (ULN) (unless due to Gilbert's syndrome, then ≤3 × ULN) 2. Aspartate aminotransferase (AST) ≤2.5 × ULN (≤5 × ULN if attributable to liver metastases) 8. Adequate renal function: creatinine clearance ≥30 mL/min, Cockcroft-Gault CCr = ((140-age) × weight[kg]) / (72 × SCr[mL/min]) × 0.85, if female. 9. Adequate hematologic parameters: 1. Absolute neutrophil count (ANC) ≥1.0 × 109/L (growth factor support allowed) 2. Platelet count ≥100,000/mm3 (100 × 109/L) (transfusion and/or growth factor support allowed) 3. Hemoglobin ≥8.0 g/dL (transfusion and/or growth factor support allowed) 10. Fasting serum triglyceride must be ≤300 mg/dL; fasting serum cholesterol must be ≤350 mg/dL. 11. Minimum of 4 weeks since any major surgery, completion of radiation, or completion of prior systemic anticancer therapy, or at least 5 half-lives if the prior therapy is a single agent small-molecule therapeutic, and adequately recovered from the acute toxicities of any prior therapy, including neuropathy, to Grade ≤1. 12. Male or non-pregnant and non-breastfeeding female: 1. Females of childbearing potential must agree to use effective contraception or abstinence without interruption from 28 days prior to starting investigational product (IP) throughout 3 months after last dose of IP and have a negative serum pregnancy test (beta human chorionic gonadotropin, β-hCG) result at screening and agree to ongoing pregnancy testing during the course of the study, and after the end of study treatment. A second form of birth control is required even if she has had a tubal ligation. 2. Male patients must agree not to donate sperm and must practice abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study and throughout 3 months after last dose of IP. A second form of birth control is required even if he has undergone a successful vasectomy. 13. The patient or the patient's parent(s) or legal guardian(s) understand(s) and sign(s) the informed consent. 14. Willingness and ability to comply with scheduled visits, laboratory tests, and other study procedures.Exclusion Criteria:
1. Prior treatment with an mTOR inhibitor, including nab-sirolimus. 2. Severe (Grade ≥3) ongoing infection requiring parenteral or oral anti-infective treatment, either ongoing or completed ≤7 days prior to enrollment. 3. Patients with primary brain tumors or PEComa. 4. Patients who have any severe and/or uncontrolled medical or psychiatric conditions or other conditions that could affect their participation including: 1. Patients with meningeal carcinomatosis, leptomeningeal carcinomatosis, spinal cord compression, untreated brain metastases or symptomatic or unstable brain metastases. Note: Patients with stable brain metastases (defined as asymptomatic or no requirement for high-dose [defined as dexamethasone 10 mg daily or higher] or increasing dose of systemic corticosteroids) and without imminent need of radiation therapy are eligible. If applicable, patients must have completed brain radiation therapy and recovered adequately from any associated toxicity and/or complications prior to eligibility assessment. For patients who have received prior radiation therapy, post-treatment MRI scan should show no increase in brain lesion size/volume. 2. Unstable angina pectoris, symptomatic congestive heart failure (New York Heart Association, NYHA class III or IV), myocardial infarction ≤6 months prior to first study treatment, serious uncontrolled cardiac arrhythmia or any other clinically significant cardiac disease. 3. Pre-existing severely impaired lung function. If a patient has a pre-existing pulmonary condition, eligible patients should have a spirometry and diffusing capacity for carbon monoxide (DLCO) that is >50% of the normal predicted value and/or O2 saturation that is >88% at rest on room air (Note: spirometry and pulmonary function tests [PFTs] not required to be performed unless clinically indicated). 4. Nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the treatment with the study therapy. 5. A history of malignancies other than the one under treatment unless the patient is disease-free for more than 5 years from diagnosis. Note, controlled non-melanoma skin cancers, carcinoma in situ of the cervix, resected incidental prostate cancer, certain low grade hematologic malignancies (eg CLL, follicular lymphoma, etc), or other adequately treated carcinoma-in-situ may be eligible, after discussion with the medical monitor. 6. Uncontrolled hypertension (systolic blood pressure ≥160 mm-Hg and/or diastolic blood pressure ≥100 mm Hg). 7. Patients with history of interstitial lung disease and/or pneumonitis, or pulmonary hypertension. 8. Individuals with known human immunodeficiency virus (HIV) infection are excluded from this study as combination antiretroviral therapy could potentially result in significant pharmacokinetic interactions. In addition, these individuals are at increased risk of serious infections due to the immunosuppressive effects of mTOR inhibition. 9. Active Hepatitis B or Hepatitis C, with detectable viral load. 5. Regarding concomitant medications with significant CYP3A4 and P-gp interactions, discontinuation of strong inhibitors (eg, ketoconazole, itraconazole, voriconazole, erythromycin, clarithromycin, telithromycin, and others), strong inducers (eg, rifampin, rifabutin), and known CYP3A4 substrates with a narrow therapeutic window (eg, fentanyl, alfentanil, astemizole, cisapride, dihydroergotamine, pimozide, quinidine, or terfenadine) is required at least 5 half lives prior to receiving the first dose of nab-sirolimus, whichever is longer.Trial Details
|
Trial ID:
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries. |
NCT05103358 |
|
Phase
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use. |
Phase 2 |
|
Lead Sponsor
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data. |
Aadi Bioscience, Inc. |
|
Principal Investigator
The person who is responsible for the scientific and technical direction of the entire clinical study. |
N/A |
| Principal Investigator Affiliation | N/A |
|
Agency Class
Category of organization(s) involved as sponsor (and collaborator) supporting the trial. |
Industry |
| Overall Status | Active, not recruiting |
| Countries | Puerto Rico, South Korea, United States |
|
Conditions
The disease, disorder, syndrome, illness, or injury that is being studied. |
Tumor, Tumor, Solid, Metastasis, Metastatic Cancer, Cancer, Cancer Metastatic, Tumors, Neoplasms, Neoplasm Metastasis, Solid Tumor, Advanced Solid Tumor, Advanced Cancer, Malignant Solid Tumor, Malignant Solid Neoplasm, Malignant Neoplasm, Malignant Tumor, TSC, TSC1, TSC2, Metastatic Solid Tumor, Metastatic Neoplasm |
Study TSC-007 is a prospective phase 2, open-label, multi-institutional basket trial to determine the efficacy and safety profile of nab-sirolimus administered to patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes. Patients will be treated with single agent IV nab-sirolimus until disease progression, or unacceptable toxicity, or until in the opinion of the investigator the patient is no longer benefiting from therapy, or at patient discretion.
Arms
Experimental: Arm A: Pathogenic inactivating TSC1 alterations
Patients with pathogenic inactivating TSC1 alterations.
Experimental: Arm B: Pathogenic inactivating TSC2 alterations
Patients with pathogenic inactivating TSC2 alterations.
Interventions
Drug: - nab-sirolimus
Prospective phase 2, open-label, multi-institutional basket trial to determine the efficacy and safety of nab-sirolimus administered by IV infusion to patients
Contact a Trial Team
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.
Status
Address
Alabama Oncology
Birmingham 4049979, Alabama 4829764, 35243
Status
Address
Southern Cancer Center
Mobile 4076598, Alabama 4829764, 36607
Status
Address
Arizona Oncology Associates
Goodyear 5296266, Arizona 5551752, 85395
Status
Address
Honor Health
Phoenix 5308655, Arizona 5551752, 85016
Status
Address
Arizona Oncology Associates
Prescott Valley 5309858, Arizona 5551752, 86301
Status
Address
Yuma Regional Medical Center
Yuma 5322053, Arizona 5551752, 85364
Status
Address
PCR Oncology
Arroyo Grande 5324802, California 5332921, 93420
Status
Address
Nextgen Oncology
Beverly Hills 5328041, California 5332921, 90212
Status
Address
City of Hope
Duarte 5344147, California 5332921, 91010
Status
Address
Providence Medical Foundation (Fullerton)
Fullerton 5351247, California 5332921, 92835
Status
Address
MemorialCare
Long Beach 5367929, California 5332921, 90806
Status
Address
USC Norris Comprehensive Cancer Center
Los Angeles 5368361, California 5332921, 90033
Status
Address
UCLA - Jonsson Comprehensive Cancer Center
Los Angeles 5368361, California 5332921, 90095
Status
Address
Providence Medical Foundation (Napa)
Napa 5376095, California 5332921, 94558
Status
Address
Hoag Memorial Hospital Presbyterian
Newport Beach 5376890, California 5332921, 92663
Status
Address
Sharp HealthCare
San Diego 5391811, California 5332921, 92123
Status
Address
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco 5391959, California 5332921, 94115
Status
Address
Ridley-Tree Cancer Center
Santa Barbara 5392952, California 5332921, 93105
Status
Address
Sarcoma Oncology Research Center
Santa Monica 5393212, California 5332921, 90403
Status
Address
Providence Medical Foundation
Santa Rosa 5393287, California 5332921, 95403
Status
Address
Stanford Cancer Center
Stanford 5398563, California 5332921, 94305
Status
Address
The Oncology Institute of Hope & Innovation
Whittier 5409059, California 5332921, 90602
Status
Address
Rocky Mountain Cancer Centers
Aurora 5412347, Colorado 5417618, 80012
Status
Address
Rocky Mountain Cancer Centers
Boulder 5574991, Colorado 5417618, 80303
Status
Address
Rocky Mountain Cancer Centers
Colorado Springs 5417598, Colorado 5417618, 80907
Status
Address
Rocky Mountain Cancer Centers (Williams St)
Denver 5419384, Colorado 5417618, 80218
Status
Address
Rocky Mountain Cancer Centers
Denver 5419384, Colorado 5417618, 80220
Status
Address
Rocky Mountain Cancer Centers
Lakewood 5427946, Colorado 5417618, 80228
Status
Address
Rocky Mountain Cancer Centers
Littleton 5429032, Colorado 5417618, 80120
Status
Address
Rocky Mountain Cancer Centers
Lone Tree 5429208, Colorado 5417618, 80124
Status
Address
Rocky Mountain Cancer Centers
Longmont 5579276, Colorado 5417618, 80501
Status
Address
Rocky Mountain Cancer Centers
Pueblo 5435464, Colorado 5417618, 81008
Status
Address
Rocky Mountain Cancer Centers
Thornton 5441492, Colorado 5417618, 80260
Status
Address
Hartford Healthcare
Hartford 4835797, Connecticut 4831725, 06102
Status
Address
Eastern Connecticut Hematology and Oncology
Norwich 4839843, Connecticut 4831725, 06360
Status
Address
Florida Cancer Specialists - North Division
Altamonte Springs 4145941, Florida 4155751, 32701
Status
Address
Florida Cancer Specialists - South Division
Bonita Springs 4148533, Florida 4155751, 34135
Status
Address
Florida Cancer Specialists - South Division
Bradenton 4148708, Florida 4155751, 34205
Status
Address
Florida Cancer Specialists - South Division
Bradenton 4148708, Florida 4155751, 34211
Status
Address
Florida Cancer Specialists - North Division
Brandon 4148757, Florida 4155751, 33511
Status
Address
Florida Cancer Specialists - South Division
Cape Coral 4149962, Florida 4155751, 33909
Status
Address
Florida Cancer Specialists - North Division
Clearwater 4151316, Florida 4155751, 33761
Status
Address
Cancer Specialist - East
Daytona Beach 4152872, Florida 4155751, 32117
Status
Address
Holy Cross Hospital
Fort Lauderdale 4155966, Florida 4155751, 33308
Status
Address
Florida Cancer Specialists South Division
Fort Myers 4155995, Florida 4155751, 33901
Status
Address
Florida Cancer Specialists - South
Fort Myers 4155995, Florida 4155751, 33905
Status
Address
Florida Cancer Specialists - South
Fort Myers 4155995, Florida 4155751, 33908
Status
Address
Florida Cancer Specialists - North Division
Gainesville 4156404, Florida 4155751, 32605
Status
Address
Cancer Specialists of North Florida
Jacksonville 4160021, Florida 4155751, 32256
Status
Address
The Oncology Institute of Hope and Innovation
Lakeland 4161438, Florida 4155751, 33812
Status
Address
TOI Florida
Lakeland 4161438, Florida 4155751, 33812
Status
Address
Florida Cancer Specialists - North Division
Largo 4161580, Florida 4155751, 33770
Status
Address
Florida Cancer Specialists - North Division
Lecanto 4161733, Florida 4155751, 34461
Status
Address
Florida Cancer Specialists - South Division
Naples 4165565, Florida 4155751, 34102
Status
Address
Florida Cancer Specialists - North Division
Ocala 4166673, Florida 4155751, 34474
Status
Address
Ocala Oncology
Ocala 4166673, Florida 4155751, 34474
Status
Address
Florida Cancer Specialists - North Division
Orange City 4167055, Florida 4155751, 32763
Status
Address
Florida Cancer Specialists - North Division
Orlando 4167147, Florida 4155751, 32806
Status
Address
Florida Cancer Specialists - South Division
Port Charlotte 4169130, Florida 4155751, 33980
Status
Address
Florida Cancer Specialists - South Division
Sarasota 4172131, Florida 4155751, 34232
Status
Address
Florida Cancer Specialists - South Division
Sarasota 4172131, Florida 4155751, 34236
Status
Address
Florida Cancer Specialists and Research Institute - North Division
St. Petersburg 4171563, Florida 4155751, 33705
Status
Address
Florida Cancer Specialists - North
St. Petersburg 4171563, Florida 4155751, 33707
Status
Address
Florida Cancer Specialist - East
Stuart 4174201, Florida 4155751, 34994
Status
Address
Florida Cancer Specialists - North Division
Tampa 4174757, Florida 4155751, 33607
Status
Address
Florida Cancer Specialists - North Division
Tavares 4174861, Florida 4155751, 32778
Status
Address
Florida Cancer Specialists - North Division
Trinity 4047906, Florida 4155751, 34655
Status
Address
Florida Cancer Specialists - South Division
Venice 4176380, Florida 4155751, 34285
Status
Address
Florida Cancer Specialists - South Division
Venice 4176380, Florida 4155751, 34292
Status
Address
Florida Cancer Specialists - East
Vero Beach 4176409, Florida 4155751, 32960
Status
Address
Florida Cancer Specialists - East
Wellington 4177703, Florida 4155751, 33414
Status
Address
Florida Cancer Specialists - East
West Palm Beach 4177887, Florida 4155751, 33401
Status
Address
Morehouse School of Medicine
Atlanta 4180439, Georgia 4197000, 30303
Status
Address
Hawaii Cancer Center
Honolulu 5856195, Hawaii 5855797, 96813
Status
Address
Hope and Healing Cancer Services
Hinsdale 4896012, Illinois 4896861, 60521
Status
Address
Northwest Oncology and Hematology
Rolling Meadows 4908052, Illinois 4896861, 60008
Status
Address
Urology of Indiana
Carmel 4255466, Indiana 4921868, 46032
Status
Address
Fort Wayne Medical Oncology and Hematology
Fort Wayne 4920423, Indiana 4921868, 46804
Status
Address
Goshen Health
Goshen 4920808, Indiana 4921868, 46526
Status
Address
Our Lady of the Lake
Baton Rouge 4315588, Louisiana 4331987, 70817
Status
Address
Pontchartrain
Hammond 4326868, Louisiana 4331987, 70403
Status
Address
American Oncology Partners of Maryland PA (Center for Cancer & Blood Disorders)
Bethesda 4348599, Maryland 4361885, 20817
Status
Address
Frederick Health
Frederick 4355585, Maryland 4361885, 21702
Status
Address
Maryland Oncology Hematology
Rockville 4367175, Maryland 4361885, 20850
Status
Address
Dana Farber Cancer Institute
Boston 4930956, Massachusetts 6254926, 02215
Status
Address
Southcoast Centers for Cancer Care
Fairhaven 4936087, Massachusetts 6254926, 02719
Status
Address
Barbara Ann Karmanos Cancer Institute
Detroit 4990729, Michigan 5001836, 48201
Status
Address
Sparrow Hospital
Lansing 4998830, Michigan 5001836, 48912
Status
Address
Minnesota Oncology Hematology
Minneapolis 5037649, Minnesota 5037779, 55404
Status
Address
Central Care Cancer Center
Bolivar 4377835, Missouri 4398678, 65613
Status
Address
Lake Regional
Osage Beach 4402040, Missouri 4398678, 65065
Status
Address
Mosaic Life Care
Saint Joseph 4407010, Missouri 4398678, 64507
Status
Address
Oncology Hematology Associates
Springfield 4409896, Missouri 4398678, 65807
Status
Address
Washington University School of Medicine
St Louis 4407066, Missouri 4398678, 63110
Status
Address
Nebraska Cancer Specialists
Grand Island 5069297, Nebraska 5073708, 68803
Status
Address
Nebraska Methodist Hospital
Omaha 5074472, Nebraska 5073708, 68114
Status
Address
OptumCare Cancer Care-Parent
Las Vegas 5506956, Nevada 5509151, 89102
Status
Address
Comprehensive Cancer Centers of Nevada
Las Vegas 5506956, Nevada 5509151, 89169
Status
Address
New Jersey Cancer Care and Blood Disorders
Belleville 5095549, New Jersey 5101760, 07109
Status
Address
Englewood Hospital and Medical Center
Englewood 5097672, New Jersey 5101760, 07631
Status
Address
Summit Medical Group - NJ
Florham Park 5098095, New Jersey 5101760, 07932
Status
Address
Atlantic Health System - Morristown Medical Center
Morristown 5101427, New Jersey 5101760, 07960
Status
Address
Roswell Park Comprehensive Cancer Center
Buffalo 5110629, New York 5128638, 14263
Status
Address
HOACNY
East Syracuse 5116079, New York 5128638, 13057
Status
Address
Cayuga Medical Center
Ithaca 5122432, New York 5128638, 14850
Status
Address
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
New York 5128581, New York 5128638, 10065
Status
Address
Southeastern Medical Oncology
Goldsboro 4468261, North Carolina 4482348, 27534
Status
Address
Sanford Health-Fargo
Fargo 5059163, North Dakota 5690763, 58102
Status
Address
Aultman Medical Group
Canton 5149222, Ohio 5165418, 44708
Status
Address
TriHealth
Cincinnati 4508722, Ohio 5165418, 45220
Status
Address
University of Cincinnati (UC) - Cancer Institute
Cincinnati 4508722, Ohio 5165418, 45627
Status
Address
Cleveland Clinic
Cleveland 5150529, Ohio 5165418, 44195
Status
Address
The Toledo Clinic
Toledo 5174035, Ohio 5165418, 43623
Status
Address
Oklahoma State University (OSU) - Stephenson Cancer Center
Oklahoma City 4544349, Oklahoma 4544379, 73104
Status
Address
Oklahoma Cancer Specialist
Tulsa 4553433, Oklahoma 4544379, 74146
Status
Address
Gettysburg-PCSRI
Gettysburg 4558183, Pennsylvania 6254927, 17325
Status
Address
Alliance Cancer Specialists
Langhorne 5197140, Pennsylvania 6254927, 19047
Status
Address
Thomas Jefferson University
Philadelphia 4560349, Pennsylvania 6254927, 19107
Status
Address
Cancer Care Associates of York - Parent
York 4562407, Pennsylvania 6254927, 17403
Status
Address
Prisma Health Cancer Institute
Greenville 4580543, South Carolina 4597040, 29605
Status
Address
Avera Cancer Institute
Sioux Falls 5231851, South Dakota 5769223, 57105
Status
Address
Sanford Health
Sioux Falls 5231851, South Dakota 5769223, 57117
Status
Address
Sarah Cannon and HCA Research Institute
Dickson 4618057, Tennessee 4662168, 37055
Status
Address
Sarah Cannon and HCA Research Institute
Franklin 4623560, Tennessee 4662168, 37067
Status
Address
Sarah Cannon and HCA Research Institute
Gallatin 4624180, Tennessee 4662168, 37066
Status
Address
West Cancer Center
Germantown 4624601, Tennessee 4662168, 38138
Status
Address
Sarah Cannon and HCA Research Institute
Henderson 4628695, Tennessee 4662168, 37075
Status
Address
Sarah Cannon and HCA Research Institute
Hermitage 4628929, Tennessee 4662168, 37076
Status
Address
Sarah Cannon and HCA Research Institute
Lebanon 4636045, Tennessee 4662168, 37090
Status
Address
Baptist Cancer Center
Memphis 4641239, Tennessee 4662168, 38120
Status
Address
Sarah Cannon and HCA Research Institute
Murfreesboro 4644312, Tennessee 4662168, 37129
Status
Address
Sarah Cannon and HCA Research Institute
Nashville 4644585, Tennessee 4662168, 37203
Status
Address
Sarah Cannon and HCA Research Institute
Nashville 4644585, Tennessee 4662168, 37205
Status
Address
Sarah Cannon and HCA Research Institute
Nashville 4644585, Tennessee 4662168, 37207
Status
Address
Sarah Cannon and HCA Research Institute
Nashville 4644585, Tennessee 4662168, 37211
Status
Address
Sarah Cannon and HCA Research Institute
Shelbyville 4657077, Tennessee 4662168, 37160
Status
Address
Sarah Cannon and HCA Research Institute
Smyrna 4658590, Tennessee 4662168, 37167
Status
Address
Mary Crowley Cancer Research
Dallas 4684888, Texas 4736286, 75230
Status
Address
Texas Oncology - DFW
Dallas 4684888, Texas 4736286, 75246
Status
Address
Texas Oncology
El Paso 5520993, Texas 4736286, 79915
Status
Address
MD Anderson Cancer Center
Houston 4699066, Texas 4736286, 77030
Status
Address
Oncology Consultants
Houston 4699066, Texas 4736286, 77030
Status
Address
Arizona Oncology Associates
Irving 4700168, Texas 4736286, 75063
Status
Address
Lumi Research
Kingwood 7534469, Texas 4736286, 77339
Status
Address
Texas Oncology Central-South
McAllen 4709796, Texas 4736286, 78503
Status
Address
South Texas Accelerated Research Therapeutics (START)
San Antonio 4726206, Texas 4736286, 78229
Status
Address
Texas Oncology
Tyler 4738214, Texas 4736286, 75702
Status
Address
Community Cancer Trials of Utah
Ogden 5779206, Utah 5549030, 84405
Status
Address
Utah Cancer Specialists
Salt Lake City 5780993, Utah 5549030, 84106
Status
Address
Virginia Cancer Specialists
Fairfax 4758023, Virginia 6254928, 22031
Status
Address
Hematology Oncology Associates of Fredericksburg
Fredericksburg 4760059, Virginia 6254928, 22408
Status
Address
Virginia Urology
Richmond 4781708, Virginia 6254928, 23235
Status
Address
University of Washington Cancer Consortium
Seattle 5809844, Washington 5815135, 98109
Status
Address
Spokane Urology
Spokane 5811696, Washington 5815135, 99202
Status
Address
Cancer Care Northwest
Spokane 5811696, Washington 5815135, 99216
Status
Address
Northwest Medical Specialties
Tacoma 5812944, Washington 5815135, 98405
Status
Address
ThedaCare
Appleton 5244080, Wisconsin 5279468, 54911
Status
Address
Gunderson Health System
La Crosse 5258957, Wisconsin 5279468, 54601
Status
Address
University of Wisconsin - Carbone Cancer Center
Madison 5261457, Wisconsin 5279468, 53705
International Sites
Status
Address
Pan Oncology Trials, LLC
San Juan 4568127, , 00935
Status
Address
Inje University Haeundae Paik Hospital
Busan 1838524, , 48108
Status
Address
Seoul National University Hospital
Seoul 1835848, , 03080
Status
Address
Severance Hospital, Yonsei University Health System
Seoul 1835848, , 03722
Status
Address
Asan Medical Center
Seoul 1835848, , 05505
Status
Address
Samsung Medical Center
Seoul 1835848, , 06351
Status
Address
Korea University Guro Hospital
Seoul 1835848, , 08308
